fb-pixelHaemonetics cuts its revenue forecast - The Boston Globe Skip to main content
Market Movers

Haemonetics cuts its revenue forecast

Brian Concannon is CEO of Haemonetics, of Braintree.Yoon S. Byun/Globe staff/2010

Haemonetics Corp. — it makes blood-processing systems for surgical blood salvage, blood component collections, and plasma collections — posted quarterly results that missed estimates and cut its full-year sales forecast. Total revenue growth is now estimated at 7 to 10 percent, or two points below initial guidance. Revenue fell in Europe and Asia, despite total growth of 24 percent to $219.5 million. The company had a net loss of $7.9 million and a per-share loss of 15 cents.